Tags

Type your tag names separated by a space and hit enter

Her-2/neu gene amplification in ductal carcinoma in situ of the breast.
Cancer Epidemiol Biomarkers Prev. 2002 Jun; 11(6):587-90.CE

Abstract

This study evaluated the relative frequencies of HER-2/neu gene amplification in ductal carcinoma in situ (DCIS)-associated invasive breast cancer and DCIS alone. We examined archival tissue samples of 100 DCIS lesions with an invasive component (cases) and 100 without an invasive component (controls), with cases and controls matched by pathologic nuclear grade. HER-2/neu gene amplification was determined by fluorescence in situ hybridization. We compared HER-2/neu gene amplification in DCIS lesions only, irrespective of the presence or absence of an invasive component. HER-2/neu gene amplification occurred significantly less frequently in the cases (26%) than in the controls (40%), with an odds ratio of 0.35 (95% confidence interval, 0.17-0.72; P < 0.004) after adjustment for pathologic and quantitative-image-analyzed morphometric nuclear grade. The HER-2/neu gene also was amplified more frequently in higher- than in lower-grade DCIS alone (56% versus 19%, respectively; P < 0.0001) or in higher- than in lower-grade DCIS with invasive cancer (44% versus 2%, respectively; P < 0.00001). Future studies should examine the potential roles of HER-2/neu and other biomarkers (e.g., p21 and Rb) as markers of the risk of DCIS patients for invasive breast cancer and as molecular targets of chemoprevention in breast intraepithelial neoplasia.

Authors+Show Affiliations

Departments of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

12050101

Citation

Hoque, Ashraful, et al. "Her-2/neu Gene Amplification in Ductal Carcinoma in Situ of the Breast." Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, vol. 11, no. 6, 2002, pp. 587-90.
Hoque A, Sneige N, Sahin AA, et al. Her-2/neu gene amplification in ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev. 2002;11(6):587-90.
Hoque, A., Sneige, N., Sahin, A. A., Menter, D. G., Bacus, J. W., Hortobagyi, G. N., & Lippman, S. M. (2002). Her-2/neu gene amplification in ductal carcinoma in situ of the breast. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, 11(6), 587-90.
Hoque A, et al. Her-2/neu Gene Amplification in Ductal Carcinoma in Situ of the Breast. Cancer Epidemiol Biomarkers Prev. 2002;11(6):587-90. PubMed PMID: 12050101.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Her-2/neu gene amplification in ductal carcinoma in situ of the breast. AU - Hoque,Ashraful, AU - Sneige,Nour, AU - Sahin,Aysegul A, AU - Menter,David G, AU - Bacus,James W, AU - Hortobagyi,Gabriel N, AU - Lippman,Scott M, PY - 2002/6/7/pubmed PY - 2002/7/24/medline PY - 2002/6/7/entrez SP - 587 EP - 90 JF - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology JO - Cancer Epidemiol Biomarkers Prev VL - 11 IS - 6 N2 - This study evaluated the relative frequencies of HER-2/neu gene amplification in ductal carcinoma in situ (DCIS)-associated invasive breast cancer and DCIS alone. We examined archival tissue samples of 100 DCIS lesions with an invasive component (cases) and 100 without an invasive component (controls), with cases and controls matched by pathologic nuclear grade. HER-2/neu gene amplification was determined by fluorescence in situ hybridization. We compared HER-2/neu gene amplification in DCIS lesions only, irrespective of the presence or absence of an invasive component. HER-2/neu gene amplification occurred significantly less frequently in the cases (26%) than in the controls (40%), with an odds ratio of 0.35 (95% confidence interval, 0.17-0.72; P < 0.004) after adjustment for pathologic and quantitative-image-analyzed morphometric nuclear grade. The HER-2/neu gene also was amplified more frequently in higher- than in lower-grade DCIS alone (56% versus 19%, respectively; P < 0.0001) or in higher- than in lower-grade DCIS with invasive cancer (44% versus 2%, respectively; P < 0.00001). Future studies should examine the potential roles of HER-2/neu and other biomarkers (e.g., p21 and Rb) as markers of the risk of DCIS patients for invasive breast cancer and as molecular targets of chemoprevention in breast intraepithelial neoplasia. SN - 1055-9965 UR - https://www.unboundmedicine.com/medline/citation/12050101/Her_2/neu_gene_amplification_in_ductal_carcinoma_in_situ_of_the_breast_ L2 - http://cebp.aacrjournals.org/cgi/pmidlookup?view=long&amp;pmid=12050101 DB - PRIME DP - Unbound Medicine ER -